Resistance to microbial infection--vaccines in theory and practice

Vaccines produced by conventional means to control major infectious diseases of man and animals

This chapter reviews the development of some of vaccines and their use in controlling such major diseases as diphtheria, rinderpest, Newcastle disease, smallpox, pertussis, yellow fever, rabies, etc. Park–Williams Number 8 (PW8) strain is used to make diphtherial toxoid for vaccines. As a source of toxin, it is rendered nontoxic by incubation with formalin under alkaline conditions. The product's retention of antigenicity, enabling it to induce antitoxin antibodies, makes it an excellent pediatric vaccine. Vaccine against Rinderpest Virus was developed by Koch in 1897 by administering bile from infected cattle. Animals that survived were permanently immune. Formalin- and chloroform-inactivated vaccines were developed using tissues from the infected animals. For the control of Newcastle disease, a number of attenuated live-virus vaccines have been developed which are widely used to control the disease. The Bl strain, the LaSota strain, and the F strain are used to immunize birds of all ages by different routes, including by addition to drinking water and by spraying. Protection against rabies correlates with SN antibody, which can be assessed by a number of tests. Pasteur's classical vaccine, developed from infected spinal cord tissue dried at room temperature for 3–14 days, was given in a series of 21–28 inoculations beginning with material dried the longest and progressing through material dried for only 3 days.

An enzyme-linked immunosorbent assay for detection of Brucella abortus in cattle using monoclonal antibodies

One group of 24 cattle was vaccinated with the usual calfhood dose of B. abortus strain 19 and a further 27 cattle were similarly vaccinated but as adults. Twenty-four cattle (12 from each group) and a control group of 12 cattle were subsequently challenged with B. abortus strain 544. Two monoclonal antibodies (MA (A) and MA (B) ) conjugated to horseradish peroxidase were used independently in a competitive enzyme-linked immunosorbent assay (ELISA) to test the serums. After vaccination with B. abortus strain 19, the performance of the monoclonal antibodies was in general agreement with the CFT as fewer calfhood vaccinates were positive 12 weeks after vaccination to the ELISA with MA (A) and MA (B) than adult vaccinates. After challenge, MA (A) and MA (B) ELISA tests detected the infected cattle earlier than the CFT, but more positive reactions occurred in the cattle that proved uninfected at slaughter.

Vaccination against experimental staphylococcosis in sheep -- observations on bacteriology and pathology following challenge

Sheep were vaccinated with a killed Staphylococcus aureus vaccine (2 doses) which had been cultured in vitro (Group 1), a killed S. aureus vaccine (2 doses) cultured in vivo (Group 2) or a single dose of a live vaccine (Group 3). Other sheep were used as non-vaccinated controls. All sheep were challenged by intravenous injection of 2.6 x 10(11) washed, viable S. aureus organisms, the vaccinated animals being given the challenge inoculum at various intervals after vaccination. The control sheep survived for 29h (mean) after challenge. Animals given killed vaccines survived longer, (particularly Group 2) if challenged less than 40 days post-vaccination, compared with those challenged more than 40 days post-vaccination. Animals in Group 3 survived longer if challenged after 40 days post-vaccination than those in Groups 1 or 2. There were no significant differences between the treatment groups for numbers of S. aureus recovered from blood in the 3h period following challenge. Histological and bacteriological evidence showed that the kidneys were more severely affected by the challenge inoculum than heart, spleen, liver or lungs. The kidneys showed both toxigenic and lymphoreticular reactions and large numbers of staphylococci were recovered more reliably from kidneys than other organs.